
Sarah Streett
Stanford University Medical Center
I am passionate about taking care of people with IBD. In my role as a gastroenterologist and a Clinical Professor of Medicine at Stanford, my practice is devoted to seeing people across the spectrum of inflammatory bowel diseases. I lead our IBD Education initiatives and established and direct our Advanced IBD Fellowship at Stanford. From a research standpoint my projects focus on optimizing clinical outcomes in reproductive health and IBD, the role of the environment, and in applying new technologies to individualizing therapy. Additionally, I lead our IBD Clinical Research Unit and am the principal site investigator in a multiple industry-sponsored clinical trials exploring new treatment targets and approaches including stem cell therapy.
Health policy and advocacy for people with digestive diseases are also a top priority and I have represented the interests of gastroenterologists and patients on Capitol Hill. Over the years I have served the American Gastroenterology Association in many capacities, including chairing the Practice Management and Economics Committee, and most recently on the Government Affairs Committee, where we published a policy position statement on Barriers to Care in IBD with recommendations for improving quality and access to care. I believe strongly in a collaborative approach across the continuum of partners in health care to improve personalized IBD care with the latest therapies and treatment approaches, and I am committed to mentoring the next generation of experts in the field.
Appearances
- DateMay 8, 2023This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
Presenter
Stanford University Medical Center - DateMay 8, 2023This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
Presenters
University of WashingtonDuke University School of MedicineStanford University Medical CenterUniversity of Pennsylvania - DateMay 9, 2023INTRODUCTION: A number of medications have been implicated as primary risk factors for microscopic colitis (MC) and guidelines recommend discontinuation of these medications as part of MC management…
Speakers
Presenter
- DateMay 21, 2024BACKGROUND: Novel noninvasive methods for evaluating disease activity in patients with inflammatory bowel disease (IBD) are needed to reduce patient burden of traditional assessments, which can involve lab sample collections for blood and stool tests, bowel preparation, and additional appointments…
Presenter
Speakers
Stanford UniversityStanford University Medical CenterThe University of British Columbia - DateMay 3, 2025
Speaker
Stanford University Medical Center